XETRA - Delayed Quote EUR

BRAIN Biotech AG (BNN.DE)

Compare
2.2400
+0.0200
+(0.90%)
At close: 5:36:27 PM GMT+2
Currency in EUR All numbers in thousands
Download
Breakdown
TTM
9/30/2024
9/30/2023
9/30/2022
9/30/2021
Total Revenue
55,010
54,631
55,335
49,509
38,389
Cost of Revenue
24,595
24,303
25,213
22,062
16,819
Gross Profit
30,415
30,328
30,122
27,447
21,570
Operating Expense
40,181
39,486
36,081
34,185
29,122
Operating Income
-9,766
-9,158
-5,959
-6,738
-7,552
Net Non Operating Interest Income Expense
-2,860
-1,983
-913
-556
-436
Pretax Income
-12,488
-10,990
-7,489
-6,165
-4,276
Tax Provision
17
111
625
176
403
Net Income Common Stockholders
-12,516
-11,127
-8,279
-6,590
-4,972
Diluted NI Available to Com Stockholders
-12,516
-11,127
-8,279
-6,590
-4,972
Basic EPS
-0.57
-0.51
-0.38
-0.30
-0.25
Diluted EPS
-0.57
-0.51
-0.38
-0.30
-0.25
Basic Average Shares
21,847.4950
21,847.4950
21,847.4950
21,847.4950
19,942.9820
Diluted Average Shares
21,847.4950
21,847.4950
21,847.4950
21,847.4950
19,942.9820
Total Operating Income as Reported
-9,459
-8,852
-5,480
-5,648
-6,548
Rent Expense Supplemental
--
1,261
1,341
1,381
993
Total Expenses
64,776
63,789
61,294
56,247
45,941
Net Income from Continuing & Discontinued Operation
-12,516
-11,127
-8,279
-6,590
-4,972
Normalized Income
-12,873.8500
-11,484.8500
-8,653
-9,335.5000
-8,710
Interest Income
--
--
4
4
11
Interest Expense
2,880
1,939
858
529
521
Net Interest Income
-2,860
-1,983
-913
-556
-436
EBIT
-9,608
-9,051
-6,631
-5,636
-3,755
EBITDA
-4,752
-4,228
-1,977
-1,296
259
Reconciled Cost of Revenue
24,595
24,303
25,213
22,062
16,819
Reconciled Depreciation
4,856
4,823
4,654
4,340
4,014
Net Income from Continuing Operation Net Minority Interest
-12,516
-11,127
-8,279
-6,590
-4,972
Total Unusual Items Excluding Goodwill
421
421
440
3,230
5,340
Total Unusual Items
421
421
440
3,230
5,340
Normalized EBITDA
-5,173
-4,649
-2,417
-4,526
-5,081
Tax Rate for Calcs
0.0002
0.0002
0.0002
0.0002
0.0003
Tax Effect of Unusual Items
63.1500
63.1500
66
484.5000
1,602
9/30/2021 - 2/9/2016

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

2HRA.DE H&R GmbH & Co. KGaA
3.6500
-3.18%
 
MZX.DE Masterflex SE
8.56
-13.71%
 
AP3.DE Air Products and Chemicals, Inc.
233.00
-5.82%
 
NTG.DE Nabaltec AG
13.80
-6.44%
 
AMC.DE Albemarle Corporation
54.89
+0.26%
 
UZU.DE Uzin Utz SE
52.50
-3.67%
 
H2A.DE H2APEX Group SCA
2.1200
+0.95%
 
FPE3.DE Fuchs SE
39.52
-2.03%
 
FPE.DE Fuchs SE
29.90
-2.13%
 
AIL.DE L'Air Liquide S.A.
160.82
-7.10%